Briacell Therapeutics’ Subsidiary, BriaPro, Files Patent Application For Immuno-Oncology Platform With Novel Multitargeting Agents

RefinitivMoins d'1 minute de lecture

Briacell Therapeutics Corp BCT:

BRIACELL’S SUBSIDIARY, BRIAPRO, FILES PATENT APPLICATION FOR IMMUNO-ONCOLOGY PLATFORM WITH NOVEL MULTITARGETING AGENTS

© Copyright Thomson Reuters 2025. Click For Restrictions - https://agency.reuters.com/en/copyright.html

Connectez-vous ou créez un compte gratuit à vie pour lire ces nouvelles